NanoVibronix Inc (Nasdaq: NAOV), a medical device company headquartered in Elmsford, New York, on Tuesday announced the signing of a Research Agreement with the Regents of the University of Michigan for a Randomized Control Trial (RCT) study of UroShield.
This clinical study aims to gather additional evidence supporting NanoVibronix's application to the FDA for permanent clearance of the UroShield device.
The company' proprietary technology, which utilises patented low-intensity surface acoustic wave (SAW) technology, allows for the creation of low-frequency ultrasound waves that can be used for medical applications such as disruption of biofilms and bacterial colonisation, as well as for pain relief.
NanoVibronix's primary products, PainShield and UroShield, are portable devices designed for home use without the need for medical professional assistance.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member